ライフサイエンスコーパス: measles

1 f vaccine-preventable disease outbreaks like measles.

2 virus (RSV), herpes simplex virus (HSV), and measles.

3 nation has led to outbreaks or resurgence of measles.

4 increasing number of children susceptible to measles.

5 wever, there has been a global resurgence of measles.

6 on direct and indirect costs associated with measles.

7 will more efficiently distinguish VARI from measles.

8 gional elimination and global eradication of measles.

9 eaks of vaccine-preventable diseases such as measles.

10 ne (MCV) and progress towards elimination of measles, 172 939 measles cases were reported worldwide i

11 io-Rad MFI sensitivity for detection of anti-measles and anti-mumps IgG-class antibodies in presumpti

12 In response to measles and diphtheria cases, first documented in Septem

13 utbreaks of the vaccine-preventable diseases measles and diphtheria have spread throughout the region

14 of-illness and cost-effectiveness studies of measles and measles prevention.

15 in the United States less than 20 years ago, measles and other vaccine-preventable diseases have made

16 h agencies confront the reemerging threat of measles and other vaccine-preventable diseases, findings

17 enting suffering, disability, and death from measles and other vaccine-preventable diseases.

18 y to infectious diseases including smallpox, measles and poliomyelitis.

19 zation are universal childhood vaccines (eg, measles and rotavirus vaccines).

20 Measles and rubella are important causes of morbidity an

21 R: 73-91%) and 97% (95% CR: 90-100%) for the measles and rubella components respectively, with an est

22 ons of Regional Verification Commissions for Measles and Rubella elimination advocate that the time f

23 These results will be important for measles and rubella elimination and the expansion of Jap

24 s-specific MBCs was 5 to 10 times lower than measles and rubella, and 10% of the participants had no

25 Importation of measles and vaccination delays among young children led

26 ications of vaccination with live attenuated measles and YF viruses in previously healthy individuals

27 tions (e.g. Coronavirus, EBOV, ZIKV, IAV and measles), and also topically for the successful treatmen

28 Seroprevalence rates of mumps, measles, and rubella determined by IgG enzyme-linked imm

29 NA viruses, alphavirus encephalomyelitis and measles, and was enriched with several leadership opport

30 sles vaccination in the presence of maternal measles antibodies was associated with reduced all-cause

31 We examined the prevalence of measles antibody among 12 349 newly hired HCP between 20

32 also associated with reduced prevaccination measles antibody concentrations and increased morbidity.

33 nd 25% (95% CI: 1, 43%), respectively, lower measles antibody concentrations at the 9-month visit amo

34 S were quantified in serum at inclusion, and measles antibody concentrations were assessed at inclusi

35 d with HIV-unexposed children (2860 mIU/mL), measles antibody geometric mean titers (GMTs) were signi

36 s, we identified an unrecognized outbreak of measles-associated SARI; sequence analysis implicated co

37 We investigated suspected cases of measles by conducting interviews, reviewing medical and

38 d), but offered better value (ICER <$100 000/measles case averted) or was even cost saving for travel

39 mental cost-effectiveness ratio [ICER] $4.6M/measles case averted), but offered better value (ICER <$

40 Although most measles case patients are <15 years of age, an age shift

41 the literature to identify studies examining measles cases and deaths in low-income and middle-income

42 d eliminated from the United States in 2000, measles cases and outbreaks continue to occur, resulting

43 Most measles cases during 2013-17 were programmatically preve

44 We analyzed data on measles cases from 2013-2018 reported to the World Healt

45 tes experienced historically high numbers of measles cases in 2019, despite achieving national measle

46 turning from abroad are responsible for most measles cases in the United States.

47 Polymerase chain reaction-positive (+) measles cases notified to Victoria's Department of Healt

48 symptoms postexposure, or the proportion of measles cases that had preexposure antibody concentratio

49 associated rash illness (VARI) and confirmed measles cases were compared during a measles outbreak.

50 Between 2008 and 2017, 297 measles cases were notified, of whom 190 (64%) were incl

51 From 2001 to 2016, 553 imported measles cases were reported to the Centers for Disease C

52 ress towards elimination of measles, 172 939 measles cases were reported worldwide in 2017.

53 aboratory-confirmed infant (aged <12 months) measles cases with rash onset during March-September 201

54 logical, clinical, and laboratory profile of measles cases with waning immunity with other measles ca

55 Waning immunity among measles cases, associated with secondary vaccine failure

56 mong US international travelers could reduce measles cases, but are costly.

57 egy projected 22 imported and 66 US-acquired measles cases, costing $14.8M per 10M travelers.

58 13 through 2018, there were 899 800 reported measles cases, of which 57% occurred unvaccinated or und

59 l reductions have been made in the number of measles cases, with an estimated 20 million deaths avert

60 easles cases with waning immunity with other measles cases.

61 Measles caused elimination of 11 to 73% of the antibody

62 Despite improvements in reported coverage of measles-containing vaccine (MCV) and progress towards el

63 ation (WHO) recommends an additional dose of measles-containing vaccine (MCV) for human immunodeficie

64 ugh routine immunization (RI), with those of measles-containing vaccine (MCV) for which SIAs are also

65 Vaccinating infants with a first dose of measles-containing vaccine (MCV1) before 9 months of age

66 etanus-pertussis vaccine (DTP1) or the first measles-containing vaccine (MCV1).

67 15-18 months, concomitantly with second-dose measles-containing vaccine (MCV2).

68 4%) waning immunity cases reported receiving measles-containing vaccines; 1 case had 2 documented dos

69 95% (the threshold for measles elimination), measles continues to cause large epidemics.

70 n on this "canonical path" is driven by both measles control activities and demographic factors, whic

71 and gray literature for articles reporting a measles correlate of protection.

72 t the serologic correlate of protection from measles disease is 120 mIU/mL.

73 portant proportion of subjects immunized for measles do not show a protective IgG titer in the 10 yea

74 ry infections likely increased deaths due to measles during wave 2.

75 pathogens, including the viruses that cause measles, Ebola and rabies.

76 ntiviral pseudoviruses expressing influenza, measles, Ebola, Lassa or vesicular stomatitis virus enve

77 e adults by 17-35%, increasing the chance of measles elimination before 2045 up to 78.9-96.5%.

78 l World Health Organization regions have set measles elimination goals.

79 decade has been above 95% (the threshold for measles elimination), measles continues to cause large e

80 optimally effective is a crucial step toward measles elimination; however, the relationship between c

81 for understanding the current persistence of measles epidemics in China.

82 ontributes to impede the spread of sustained measles epidemics, rather than favoring it.

83 n gain insight into their current and future measles epidemiology and select appropriate strategies t

84 y to estimate the potential impact on future measles epidemiology of a novel immunization strategy, t

85 , and ethical arguments for setting a global measles eradication goal.

86 though some clinical differences were noted, measles exposure and identification of the vaccine strai

87 itted human pathogens, such as influenza and measles, generate sustained exponential growth in incide

88 Measles genotype B3 and rubella genotype 2B were detecte

89 Measles has been analyzed extensively as a paradigm for

90 e factors contributing to the persistency of measles, here we develop a model-inference system to inf

91 virologic surveillance of sporadic cases of measles; however, they can be a useful tool for the expa

92 red five widely used, commercially available measles IgG test platforms using a set of 223 well-chara

93 rformance characteristics of tests to detect measles IgG, we compared five widely used, commercially

94 of these (15%) did not show protective anti-measles IgG.

95 our estimates of a 2- to 3-year duration of measles "immune-amnesia." We show that periodicity has a

96 Waning measles immunity among vaccinated individuals may result

97 Measles immunity testing was performed in patients witho

98 further work is required to characterize the measles immunity threshold.

99 1957 was reviewed for serologic evidence of measles immunity.

100 rs [HCWs]) to investigate the persistence of measles immunoglobulin G (IgG).

101 Measles importations and the subsequent spread from US t

102 ould amplify outbreaks(2-4), as happened for measles in 2019(5,6).

103 porally detailed urban incidence dataset for measles in England and Wales, from 1944 to the infection

104 liest possible date for the establishment of measles in human populations.

105 The dynamics of measles in London, in particular, has acted as a prototy

106 An outbreak of measles in New York City began when one unvaccinated chi

107 s among young children led to an outbreak of measles in New York City.

108 Here, we study measles in Pakistan, and we demonstrate that campaign ti

109 Despite the elimination of measles in the United States (US) in the year 2000, case

110 Measles incidence and mortality rates have significantly

111 kar and McCarthy suggest that periodicity in measles incidence artifactually drives our estimates of

112 y be confounded by the 2-year periodicity of measles incidence in the areas studied.

113 viduals and lead to complications, including measles inclusion body encephalitis (MIBE).

114 y and neutralizing-antibody titers >40000 to measles (indicating reinfection) were identified in 18 (

115 , mumps, and rubella), but were confirmed in measles-infected macaques.

116 Measles infection among children hospitalized with respi

117 d (HEU) children may be at increased risk of measles infection due to waning of immunity following va

118 The reduction in humoral immune memory after measles infection generates potential vulnerability to f

119 Apart from its global health importance, measles is a paradigm for the low-dimensional mechanisti

120 rts to ensure a world where no child dies of measles, is NOW!

121 uctural complexity and dimensionality, for a measles-like infectious disease.

122 dministered with either DTP1, DTP2, DTP3, or measles (Meas)1.

123 type b, Streptococcus pneumoniae, rotavirus, measles, meningitis A, rubella, and yellow fever to appr

124 Measles morbidity and mortality rates are greatest in ch

125 is continued uncertainty about the burden of measles mortality and the effect of measles vaccination.

126 rus nosocomial transmission likely decreases measles mortality.

127 e substantially reduced the global burden of measles mortality.

128 ises much of the persisting global childhood measles mortality.

129 mportant human and animal pathogens, such as measles, mumps, and parainfluenza viruses and the deadly

130 Vaccination against measles, mumps, and rubella (MMR) and yellow fever (YF)

131 tly retracted by the journal, suggested that measles, mumps, and rubella (MMR) vaccine causes autism.

132 93.3, and 74.2% were positive by the Bio-Rad measles, mumps, and rubella IgG MFIs, respectively.

133 We examined if revaccination with the live measles, mumps, and rubella vaccine (MMR) is associated

134 oversies in the United States, including (1) measles, mumps, and rubella vaccine and autism; (2) thim

135 observed in infants vaccinated against MMR (measles, mumps, and rubella), but were confirmed in meas

136 1, and 93.5% of HCWs presumptively immune to measles, mumps, and VZV (a rubella IFA was unavailable).

137 Among HCWs fully vaccinated against measles, mumps, and VZV, Bio-Rad MFI/Bion IFA positivity

138 Medically important paramyxoviruses, such as measles, mumps, parainfluenza, Nipah, and Hendra viruses

139 The hypothesized link between the measles, mumps, rubella (MMR) vaccine and autism continu

140 pproval as a qualitative diagnostic test for measles, mumps, rubella, and varicella virus immunity, i

141 Immunity to measles, mumps, rubella, and varicella-zoster viruses (V

142 (5.5%), and 22 (1.9%) were seronegative for measles, mumps, rubella, and VZV, respectively, and 165

143 Among HCWs presumptively immune to measles, mumps, rubella, and VZV, the Bio-Rad MFI was po

144 Measles-mumps-rubella (MMR) vaccine (given as either MMR

145 Two thousand immunized (2 doses of measles-mumps-rubella [MMR] vaccine) students and reside

146 acted small case series in Lancet connecting measles-mumps-rubella vaccinations with autism, small ca

147 d varicella vaccine (V) dose given after one measles-mumps-rubella vaccine (MMR) dose (MMR + V), vers

148 A third measles-mumps-rubella vaccine (MMR) dose (MMR3) is recom

149 body responses and safety of a third dose of measles-mumps-rubella vaccine (MMR-3) in 150 young adult

150 nt phase 3 clinical trial (NCT01681992) of 2 measles-mumps-rubella vaccines were used to compare anti

151 vaccine efficacy of two doses of a combined measles-mumps-rubella-varicella vaccine (MMRV), one live

152 ubella (MMR) vaccine (given as either MMR or measles-mumps-rubella-varicella vaccine and collectively

153 ephalomyocarditis (EMCV), influenza A (IAV), measles (MV), Sendai (SV), or vesicular stomatitis (VSV)

154 Similar results were found for 16 measles-negative samples that were confirmed as rubella

155 genome is largely exposed in fully assembled measles nucleocapsids.

156 e data analysed case-based data for cases of measles occurring during 2013-17 submitted to WHO by its

157 cinated child returned home from Israel with measles; onset of rash occurred on September 30, 2018, 9

158 similar to those in humans given inactivated measles or respiratory syncytial virus vaccines.

159 We describe a measles outbreak and control measures implemented at a p

160 Surveillance data from a large measles outbreak in Mongolia suggested increased case fa

161 In late 2018-summer of 2019, a measles outbreak occurred in the New York City area, wit

162 a systematic risk assessment during a large measles outbreak to identify and protect at-risk SOT pat

163 The median total cost per measles outbreak was $152 308 (range, $9862-$1 063 936);

164 nfirmed measles cases were compared during a measles outbreak.

165 may need to be reevaluated in the setting of measles outbreaks and decreased herd immunity.

166 These findings highlight how costly measles outbreaks can be, the value of this information

167 Understanding the cost associated with measles outbreaks can inform cost-of-illness and cost-ef

168 Although ARs were low, measles outbreaks can occur in intense-exposure settings

169 sation on only the child deaths averted from measles outbreaks during the COVID-19 risk period.

170 the year 2000, cases continue to occur, with measles outbreaks having occurred in various jurisdictio

171 Previous research has shown that measles outbreaks in high-coverage contexts are driven b

172 nefits to only the child deaths averted from measles outbreaks, the benefit-risk ratio to the househo

173 h 2018 that presented cost estimates from 11 measles outbreaks.

174 uptake in the context of recent and ongoing measles outbreaks.

175 ictable changes in the size and frequency of measles outbreaks.

176 ance of more broadly documenting the cost of measles outbreaks.

177 e extracted data on case-fatality ratios for measles overall and by age, where possible.

178 tients residing in outbreak areas received a measles patient education handout.

179 ion among local small population clusters in measles persistence.

180 nd cost-effectiveness studies of measles and measles prevention.

181 th other members of NNS RNA viruses, such as measles, rabies virus, and Ebola virus.

182 Inpatient admission, 7-21 days before measles rash onset, for pneumonia or influenza (amOR: 4.

183 High-income countries are experiencing measles reemergence as the result of suboptimal vaccine

184 gh-risk settings has the potential to reduce measles-related morbidity and mortality.

185 ruses, including the human pathogens rabies, measles, respiratory syncytial virus, Nipah, and Ebola,

186 (7% of the agency) had been involved in the measles response.

187 ecipitously, dramatically increasing risk of measles resurgence.

188 oped a systematic 3-part approach to address measles risk in our adult SOT program through: (a) ident

189 Mumps, measles, rubella, and varicella-zoster viruses (MMRV) ma

190 tection among 1- to 6-year-olds was high for measles, rubella, diphtheria, and tetanus (91%-98%; 95%

191 collected to estimate seroprotection against measles, rubella, diphtheria, and tetanus, using Luminex

192 of whom had the recommended 2 doses of mumps-measles-rubella (MMR) vaccine.

193 94%] of 507) was non-inferior to that in the measles-rubella group (473 [94%] of 506 infants; differe

194 98%] of 507) was non-inferior to that in the measles-rubella group (499 [99%] of 506; difference -0.8

195 asles-rubella plus LJEV group and 506 in the measles-rubella group completed the study.

196 JEV group) or measles-rubella vaccine alone (measles-rubella group).

197 asles-rubella plus LJEV group and 548 to the measles-rubella group.

198 6 to 1.1]) and rubella seroconversion in the measles-rubella plus LJEV group (478 [94%] of 507) was n

199 r vaccination, measles seroconversion in the measles-rubella plus LJEV group (496 [98%] of 507) was n

200 e infants assigned to each group, 507 in the measles-rubella plus LJEV group and 506 in the measles-r

201 d infants, 545 were randomly assigned to the measles-rubella plus LJEV group and 548 to the measles-r

202 les-rubella vaccine and LJEV simultaneously (measles-rubella plus LJEV group) or measles-rubella vacc

203 neously (measles-rubella plus LJEV group) or measles-rubella vaccine alone (measles-rubella group).

204 re randomly assigned (1:1) to receive either measles-rubella vaccine and LJEV simultaneously (measles

205 vaccine (MCV-A) at 15 months, in addition to measles-rubella vaccine at both 9 and 15 months.

206 at 8 months of age on the immunogenicity of measles-rubella vaccine.

207 6 weeks after vaccination, measles seroconversion in the measles-rubella plus LJEV

208 MCVs among seronegative HIV-infected adults, measles seropositivity at end of follow-up ranged from 0

209 Across studies, measles seroprevalence among HIV-infected adolescents an

210 w to synthesize available evidence regarding measles seroprevalence and measles vaccine immunogenicit

211 Based on similar measles seroprevalence between HIV-infected and HIV-unin

212 In MSs, measles seroprotection was similarly high among 1- to 6-

213 ated increases in morbidity and decreases in measles-specific antibody concentrations before and afte

214 the current global epidemiology, we analyzed measles surveillance data.

215 of measles viruses is an important tool for measles surveillance.

216 serological studies to directly characterize measles susceptibility is a high priority.

217 Measles-susceptible adolescents and adults, regardless o

218 combine to change the effective size of the measles-susceptible population, thereby driving the coun

219 s broadly accepted that this also applies to measles, the exact date of emergence for this disease is

220 data upon which the commonly used 120 mIU/mL measles threshold of protection is based, suggesting tha

221 the estimations of case-fatality ratios for measles, to develop a prediction model to estimate case-

222 n Italy would not be sufficient to interrupt measles transmission before 2045 because of the frequenc

223 cal and demographical characteristics key to measles transmission during 1951-2004 for three key loca

224 we develop a model-inference system to infer measles transmission dynamics in China.

225 be collected to prevent a return to endemic measles transmission in the United States.

226 ination coverage and containment in limiting measles transmission.

227 d to project future case-fatality ratios for measles up to 2030.

228 antibodies in infants born to predominantly measles-vaccinated mothers.

229 uninfected (HEU) (n = 71) children received measles vaccination (CAM-70) at 6 and 12 months of age.

230 fant PFAS exposure and antibody responses to measles vaccination as well as morbidity in a low-income

231 We evaluated persistence of antibodies to measles vaccination at 4.5 years of age in HIV-unexposed

232 Early 2-dose measles vaccination at 6 and 12 months of age was safe a

233 (n = 62) children were scheduled to receive measles vaccination at age 9 and 15-18 months.

234 Infants who first received measles vaccination before 12 months of age had a long-t

235 ly shown by hemagglutination inhibition that measles vaccination in the presence of maternal measles

236 Measles vaccination is a public health 'best buy', with

237 one or two subsequent doses of MCV than when measles vaccination is started at age 9 months or older.

238 es cases in 2019, despite achieving national measles vaccination rates above the World Health Organiz

239 ted by maternal antibodies until their first measles vaccination, between 12 and 15 months of age.

240 This provides incentive to reduce the age at measles vaccination, but immunological consequences are

241 Despite high coverage reported for measles vaccination, outbreaks continue to occur in some

242 nce base for recommendations on the need for measles vaccination.

243 urden of measles mortality and the effect of measles vaccination.

244 Half the children received two measles vaccinations (at inclusion and at 9 months of ag

245 A large-scale campaign to promote measles vaccinations has substantially reduced the numbe

246 h a Vi-conjugate vaccine coadministered with measles vaccine are planned.

247 visit among the children who had received a measles vaccine at inclusion.

248 from 1992 onwards (year of public nationwide measles vaccine availability).

249 These findings support WHO guidelines that measles vaccine be administered to potentially susceptib

250 y-reported values, the immunogenicity of the measles vaccine component was unexpectedly low (75% (95%

251 vidence regarding measles seroprevalence and measles vaccine immunogenicity, efficacy, and safety in

252 to evaluate the long-term immunogenicity of measles vaccine in a sample of medical students and resi

253 immunogenicity and safety of an early 2-dose measles vaccine regimen administered at 6 and 12 months

254 2017 regulation, which consists of offering measles vaccine to the parents of children who get vacci

255 One month after the first measles vaccine, 42.3% of HU and 46.4% of HEU children w

256 ome of interest was serological responses to measles vaccine, stratified by HIV infection status.

257 es from healthy volunteers vaccinated with a measles-vectored chikungunya vaccine candidate, MV-CHIK,

258 ocument the immunogenicity and efficacy of a measles-vectored chikungunya vaccine that shows promise

259 human parainfluenza virus type-3 (HPIV3) and measles virus (MeV) are a substantial health threat.

260 We show that the measles virus (MeV) C protein is an additional component

261 these animal models) than wt MeV.IMPORTANCE Measles virus (MeV) infection can be severe in immunocom

262 ons of chemokine CXCL10 in 288 patients with measles virus (MeV) primary infection and 16 patients wi

263 ented negative-strand RNA viruses, including measles virus (MeV), a member of the Paramyxoviridae fam

264 antibody titers to hepatitis A virus (HAV), measles virus (MeV), and cytomegalovirus (CMV).

265 Measles virus (MeV), like all viruses of the order Monon

266 Here, we generated measles virus (MeV)-based vaccine candidates expressing

267 Using a mouse model of measles virus (MV) neuronal infection, we show that MV R

268 modeling to determine the divergence date of measles virus and rinderpest virus.

269 We sequenced the genome of a 1912 measles virus and used selection-aware molecular clock m

270 operty for infection of the brain.IMPORTANCE Measles virus can invade the central nervous system (CNS

271 omplex, central nervous system (CNS)-adapted measles virus can spread outside the CNS within an infec

272 ly enrolled for serological testing for anti-measles virus immunoglobulin G antibody.

273 d children before and 2 months after natural measles virus infection.

274 Measles virus infects immune cells, causing acute immune

275 pidemiology of international importations of measles virus into the United States during the postelim

276 Measles virus is directly responsible for more than 100,

277 Measles virus neutralizing antibodies were also measured

278 Preventing measles virus nosocomial transmission likely decreases m

279 nsically disordered C-terminal domain of the measles virus nucleoprotein (N(TAIL)) and the X domain (

280 otein (N(TAIL)) and the X domain (XD) of the measles virus phosphoprotein complex.

281 Our analyses show that the measles virus potentially arose as early as the sixth ce

282 Measles virus replication occurs in the cytoplasm in ass

283 susceptible to viruses, including the YF and measles virus vaccine strains, in the absence or presenc

284 ntibodies to respiratory syncytial virus and measles virus, compared to uninfected controls.

285 ped viruses tested, including herpesviruses, Measles virus, influenza, and SARS-CoV-2.

286 ARS/MERS), human enteroviruses/rhinoviruses, measles virus, mumps virus, Hepatitis A-E Virus, Chikung

287 nfluenza virus, modest for VSV, and mild for measles virus, suggesting a greater role for viruses tha

288 nisms used by morbilliviruses, including the measles virus, to promote massive amplification within t

289 Levels of antibodies induced by the measles virus-containing vaccine have been shown to decl

290 Seven studies reporting on measles virus-specific cellular immune responses found t

291 Measurement of measles virus-specific IgG is used to assess presumptive

292 decrease in the concentration and avidity of measles virus-specific neutralizing antibodies, compared

293 Measles virus-specific neutralizing antibody concentrati

294 macaques were immunized and boosted with the measles virus-vectored chikungunya vaccine or sham-vacci

295 A new measles virus-vectored vaccine was developed to prevent

296 The genetic characterization of measles viruses is an important tool for measles surveil

297 Although measles was declared eliminated from the United States i

298 Measles was declared eliminated in the United States in

299 A total of 649 cases of measles were confirmed, with onsets of rash occurring be

300 s for such outbreaks are well understood for measles, yet the information required to make these calc